Prostatic Hyperplasia Clinical Trial
Official title:
Prostate Cancer in Benign Prostatic Hyperplasia (BPH) Patients
This retrospective cohort study will assess the association of benign prostatic hyperplasia (BPH) treatment (5-alpha reductase inhibitors (5ARI) and alpha-blocker medications) with the occurrence of prostate cancer related mortality. This study will also assess a number of secondary endpoints including prostate cancer mortality or metastatic prostate cancer, and all cause mortality.
A retrospective cohort study from 1992-2010 will be conducted using data from 4 Kaiser
sites: Kaiser Permanente Southern California (KPSC), Kaiser Permanente Northern California
(KPNC), Kaiser Permanente Northwest (KPNW), and Kaiser Permanente Colorado (KPCO). Men
treated with BPH medications, 5ARIs (with and without concomitant and/or previous
alpha-blocker use) will be compared to men treated with alpha-blockers. A matched design
will be used with each man treated with 5ARIs being matched with 5 or 6 men treated with
alpha-blockers. Men 50 years or older at the time of their first prescription for a study
defined BPH medication, initiating treatment between 1992 and 2008 with at least 1-year of
coverage in the healthcare system before the first prescription for BPH medication and at
least 3 consecutive prescriptions (90 days of supply) for a BPH medication will be eligible
for inclusion in the study. Men with a diagnosis of prostate cancer any time before the
first prescription for BPH medication, having a diagnosis of prostate cancer within 3 months
after initiation of their first BPH medication, and those treated with finasteride 1mg prior
to their BPH medication will be excluded from the study. 5ARI initiators will be matched to
alpha-blocker users in a ratio of 1:5 or 1:6 to yield an overall matching ratio of 1:5.4.
Matching factors include age (+/- 1 year), timing of BPH treatment initiation (+/- 1 year),
race, and duration of prior use of alpha-blockers. Based on the feasibility study from KPSC,
there will be approximately 284,000 men treated with BPH medications meeting eligibility
criteria for inclusion in the study sample.
The data will be analyzed using Kaplan Meier curves comparing the 5ARI vs alpha-blocker
users for the primary and secondary study outcomes, without any adjustments. Additionally, a
plot of cumulative incidence, adjusting for competing risks of death, will be constructed
allowing for the investigation of the effect of competing risks on the Kaplan-Meier
probability estimates. Crude mortality rates and incidence rates of metastatic cancer will
be calculated. Cox proportional hazard regression models will be fit to compare the primary
and secondary outcomes between groups using hazard ratios, while adjusting for pre-treatment
characteristics.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02578953 -
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
|
Phase 1 | |
| Terminated |
NCT02396420 -
Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams
|
Phase 2 | |
| Terminated |
NCT04398966 -
Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia
|
N/A | |
| Not yet recruiting |
NCT06452927 -
EEP in Patients With Urodynamically Proven DU/DA
|
N/A | |
| Completed |
NCT02947958 -
Teleconsultation in Counter-reference Between Tertiary and Primary Care for Patients With Benign Prostatic Hyperplasia
|
N/A | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT00427882 -
Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
|
Phase 4 | |
| Completed |
NCT02244320 -
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
|
N/A | |
| Completed |
NCT01254071 -
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
|
Phase 1 | |
| Recruiting |
NCT04108871 -
Whether Transperineal Prostate Biopsy Under Local-anaesthesia Using a Transperineal-access System is Non-inferior to Standard Transrectal Biopsy to Detect Prostate Cancer in Biopsy-naïve Men
|
N/A | |
| Recruiting |
NCT05686525 -
Clinical Trial on the Effectiveness of TUMT Compared to PAE in Reducing Severe LUTS in Men With BPH
|
N/A | |
| Completed |
NCT01957189 -
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
|
Phase 1 | |
| Completed |
NCT00316732 -
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
|
N/A | |
| Completed |
NCT02715401 -
PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers
|
Phase 1 | |
| Recruiting |
NCT02278679 -
Digital Rectal Exam Proficiency Tool
|
N/A | |
| Completed |
NCT01482676 -
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
|
N/A | |
| Completed |
NCT01376258 -
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
|
N/A | |
| Completed |
NCT00822952 -
Prostate Mechanical Imager (PMI) Clinical Bridging Study
|
N/A | |
| Completed |
NCT00527605 -
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
| Terminated |
NCT00563485 -
Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
|
N/A |